- Home
- DNTH vs VALN Comparison
DNTH vs VALN Comparison
Compare DNTH & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNTH
- VALN
- Stock Information
- Founded
- DNTH 2015
- VALN 2012
- Country
- DNTH United States
- VALN France
- Employees
- DNTH N/A
- VALN N/A
- Industry
- DNTH Biotechnology: Pharmaceutical Preparations
- VALN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DNTH Health Care
- VALN Health Care
- Exchange
- DNTH Nasdaq
- VALN Nasdaq
- Market Cap
- DNTH 568.6M
- VALN 542.5M
- IPO Year
- DNTH N/A
- VALN 2021
- Fundamental
- Price
- DNTH $16.86
- VALN $5.62
- Analyst Decision
- DNTH Strong Buy
- VALN Strong Buy
- Analyst Count
- DNTH 8
- VALN 3
- Target Price
- DNTH $53.00
- VALN $15.33
- AVG Volume (30 Days)
- DNTH 277.7K
- VALN 81.8K
- Earning Date
- DNTH 08-07-2025
- VALN 08-12-2025
- Dividend Yield
- DNTH N/A
- VALN N/A
- EPS Growth
- DNTH N/A
- VALN N/A
- EPS
- DNTH N/A
- VALN N/A
- Revenue
- DNTH $6,524,000.00
- VALN $201,099,222.00
- Revenue This Year
- DNTH N/A
- VALN $18.74
- Revenue Next Year
- DNTH N/A
- VALN $29.26
- P/E Ratio
- DNTH N/A
- VALN N/A
- Revenue Growth
- DNTH 102.36
- VALN 21.64
- 52 Week Low
- DNTH $13.37
- VALN $3.62
- 52 Week High
- DNTH $32.27
- VALN $8.66
- Technical
- Relative Strength Index (RSI)
- DNTH 38.63
- VALN 31.31
- Support Level
- DNTH $17.67
- VALN $5.70
- Resistance Level
- DNTH $19.58
- VALN $6.40
- Average True Range (ATR)
- DNTH 1.14
- VALN 0.20
- MACD
- DNTH -0.07
- VALN -0.05
- Stochastic Oscillator
- DNTH 3.20
- VALN 0.00
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.